News

NHS to begin offering new one-minute jab to women with ‘aggressive’ form of cancer

It follows successful clinical trials.

Emily Sergeant Emily Sergeant - 1st July 2026

The NHS is set to begin offering new immunotherapy for hundreds of women with aggressive cervical cancer across the country.

Pembrolizumab – which experts have described as being able to ‘take the handbrake off’ the body’s immune system to target cancer – will now be presented as a new treatment option for women in England with locally-advanced cervical cancer, which means the cancer has grown beyond the cervix to regions such as the pelvic wall, but not yet spread further around the body.

Trials found that adding pembrolizumab to standard chemoradiotherapy helped keep cancer ‘at bay’ for longer, and improved survival rates overall.

Two years after starting the treatment, nearly seven in 10 patients (68%) were still living without their cancer progressing, compared with 57% for those receiving chemoradiotherapy alone, according to NHS figures.

The trial also found that 82.6% of patients were still alive three years after treatment with pembrolizumab and chemoradiotherapy, compared with 74.8% with chemoradiotherapy alone.

ADVERTISEMENT

The drug is either given every three or siz weeks via an infusion, or as a ‘one-minute’ injection, alongside chemoradiotherapy.

The NHS estimates around 550 patients in England will be eligible for the treatment – which has been approved this week by the National Institute for Health and Care Excellence (NICE) – over the next two years.

ADVERTISEMENT

Patients will now receive fast-tracked access, funded by NHS England’s Cancer Drugs Fund.

“This is great news for women facing a diagnosis of aggressive cervical cancer, and represents one of the biggest improvements in treatment for this disease in recent years,” commented Professor Peter Johnson, who is the NHS National Clinical Director for Cancer.

“Combining this immunotherapy with existing treatment has had very positive effect for patients in trials, helping the body’s immune system to target cancer more effectively.

ADVERTISEMENT

Read more:

“We’re delighted it will be available for patients on the NHS as it could help hundreds more women survive and stay cancer-free in the long-term.”

Featured Image – NappyStudio (via Unsplash)